Therefore, we used CGM to investigate whether fasting glucose levels and post-breakfast glucose excursions could predict the occurrence of nocturnal asymptomatic hypoglycemia in outpatients with patients with type 1 diabetes who are receiving basal-bolus insulin therapy and incorporating insulin degludec as long-acting insulin. The gene discussed is INS; the disease is type 1 diabetes mellitus.